SpectraCure AB publishes quarterly report 1, 2021

First quarter 2021

Figures for 2021 and 2020 refer to the Group.

  • Other operating income amounted to KSEK 1,597 (1,185)
  • Result after taxes amounted to KSEK -4,773 (-3,784)
  • Basic and diluted earnings per share: SEK -0.05 (-0.04)
  • Cash flow for the period amounted to KSEK -4,309 (-3,624)
  • Solidity: 92 (86)%

Significant events during the first quarter of 2021
Spectracure strengthened the team with the consultant and business developer Johan Ingemansson.The company published a status update, a data evaluation and a continued plan for the ongoing pandemic relating to the clinical trial involving treatment of patients with recurring prostate cancer. All in all, 17 patients have completed the treatment. In conjunction with the outbreak of the pandemic, all clinical trials except those related to COVID-19 were put on hold in most hospitals around the world. The team at Memorial Sloan Kettering is standing by to commence patient treatments as soon as the situation permits. At the Princess Margaret Cancer Centre in Toronto, cancer trials have been put on hold for the time being. In addition, a two-week quarantine currently applies for travellers entering Canada, which makes the cooperation challenging. The team at Princess Margaret Cancer Centre is also standing by to commence patient treatments as soon as the situation permits. At UCLH in London, the trial was resumed on October 8, 2020, and recruitment is now underway. As previously disclosed, SpectraCure intends to apply for a so-called Accelerated Approval for the method. This will require a robust set of Phase 2 clinical data.


Significant events after the end of the period

The Nomination Committee resolved to propose that members of the board Ulf Bladin, Hans Bornefalk, Ingemar Kihlström, Katarina Svanberg and Sune Svanberg be re-elected by the Annual General Meeting of SpectraCure AB (publ) on Tuesday, May 18, 2021. Ingemar Kihlström is proposed for re-election as Chairman of the Board. Masoud Khayyami, current member of the board, has declined re-election. The Nomination Committee has decided to propose Dr. Homer Pien as a new member of the board.
Johan Folkunger, SpectraCure’s new CEO, took office on May 3, 2021.